VENETOCLAX

Venetoclax is a selective BCL2 inhibitor that restores apoptosis in malignant cells, used in CLL and AML. It produces deep remissions, especially with combination therapy. Side effects include tumor lysis syndrome, neutropenia, infections, GI upset, and anemia, requiring careful dose rampup. Only GMP materials will be supplied, logistics all according to GDP.

Category:

Product Description


Mechanism of Action

VENETOCLAX displays a highdimensional biochemical interaction profile, integrating catalyticdomain modulation, multiaxis signalling interference, mitochondrialnetwork recalibration, ionflux redistribution, membranepotential rebalancing, cytoskeletal remodelling, redoxequilibrium restructuring and transcriptionfactor pathway reprogramming. Its molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotidebinding pockets, redoxbuffer centres and polymeric scaffolding complexes, enabling wideband influence across metabolic, genomic, structural and electrophysiological layers.

At the signalling level, VENETOCLAX may reconfigure phosphorylation landscapes spanning ERK/MAPK/JNK/p38 and PI3KAKT axes, modulate Gprotein coupling states, reorganise Ca²⁺ microdomain geometry, adjust IP/DAG cascade topology, and recalibrate cAMPPKA amplitude distributions. Mitochondrial effects can include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, membranepotential polarity shifts and bidirectional stresssignal integration between ER and mitochondrial compartments.

Advanced

  • Kinomescale catalyticcascade interference mapping
  • Highresolution docking & conformationaltransition simulations
  • UPR/ERstress, mitophagy & autophagicflux network analysis
  • Full multiomics integration (RNAseq, proteomics, phosphoproteomics, metabolomics)
  • Cytoskeletal mechanics & polymerturnover/forcedistribution modelling
  • Cellfate pathway simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
  • AIdriven SAR/QSAR pipelines for compoundperformance prediction

Toxicodynamics & Hazard Spectrum

  • Rapid ROS escalation & antioxidantbuffer saturation
  • Mitochondrial fragmentation or ETCaxis suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionic-flux destabilisation
  • Cytoskeletal depolymerisation & membrane-integrity loss
  • Hyperactivation of NF-κB, STAT & IRF inflammatory regulators
  • Induction of multiaxis programmed-cell-death pathways
  • Epigenetic drift including methylation/acetylation imbalance

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C45H50ClN7O7S

Molecular Weight

868.4 g/mol

CAS Number

1257044-40-8

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Venetoclax; 1257044-40-8; ABT-199; Venclexta; GDC-0199

IUPAC/Chemical Name

4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide

InChl Key

LQBVNQSMGBZMKD-UHFFFAOYSA-N

InChl Code

InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)

References

https://pubchem.ncbi.nlm.nih.gov/compound/49846579;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download